In addition, it has also been shown that overexpression of IGF2 induces resistance to targeting agents, such as the EGFR inhibitors, osimertinib and erlotinib, by re-activating the AKT and MAPK pathways in lung cancer and cholangiocarcinoma [74]. This evidence concerns the gene AKT1 and cholangiocarcinoma.